Pharmaceutical conglomerate Allergan, in efforts to avoid a takeover by Valeant Pharmaceuticals, is reportedly seeking to merge with fellow pharma-giant Actavis.
Unnamed sources say Allergan, which manufactures Botox, is in active discussions with Actavis, though the sources noted that a deal is not guaranteed. Allergan revealed in a filing Thursday that it is in discussions with a third party about a separate merger, though did not specify with which company.
Allergan is looking to avoid a hostile takeover by Valeant in a deal valued at about $54 billion. The Botox maker has slammed the deal as “grossly inadequate” and has claimed the Canadian firm would severely cut Allergan’s research and development operations.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI